(Q44180365)

30 November 2017

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma (English)

1 reference

30 November 2017

1 reference

Ketan Sheth

1

1 reference

30 November 2017

Rohit Borker

2

1 reference

30 November 2017

Amanda Emmett

3

1 reference

30 November 2017

Kathleen Rickard

4

1 reference

30 November 2017

Paul Dorinsky

5

1 reference

30 November 2017

1 January 2002

1 reference

30 November 2017

1 reference

30 November 2017

20

1 reference

30 November 2017

13

1 reference

30 November 2017

909-918

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200220130-00004

30 November 2017

0 references

cites work

What is meant by intention to treat analysis? Survey of published randomised controlled trials

1 reference

12 December 2020

The health economics of asthma and rhinitis. I. Assessing the economic impact

1 reference

12 December 2020

Psychopathology in patients with severe asthma is associated with increased health care utilization

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

12 December 2020

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

1 reference

12 December 2020

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

12 December 2020

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

12 December 2020

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

1 reference

12 December 2020

Charge what you will ... reimbursements are shrinking

1 reference

12 December 2020

Forecasted state-specific estimates of self-reported asthma prevalence--United States, 1998

1 reference

12 December 2020

Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis.

1 reference

12 December 2020

Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma

1 reference

12 December 2020

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

12 December 2020

The cost of asthma in the emergency department and hospital

1 reference

12 December 2020

Risk factors and costs associated with an asthma attack

1 reference

12 December 2020

Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

1 reference

12 December 2020

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone

1 reference

12 December 2020

10.2165/00019053-200220130-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

30 November 2017

1031892994

0 references

Fatcat ID

release_thungy56r5f2dbb7oaqjrty6p4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/thungy56r5f2dbb7oaqjrty6p4

24 November 2022

mapped directly with Wikidata item

1 reference